Multiscan s.r.o.
About Multiscan s.r.o.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
8
Eli Lilly and Company
3
Genentech, Inc.
2
Acrotech Biopharma Inc.
1
EMD Serono Research & Development Institute, Inc.
1
Ferring Pharmaceuticals
1
Janssen Research & Development, LLC
1
Pfizer
1
Puma Biotechnology, Inc.
1
Clinical Trials at Multiscan s.r.o.
During the past decade, Multiscan s.r.o. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 13 clinical trials were completed, i.e. on
average, 108.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
2009-07-09
2019-10-04
Completed
2,840
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
2010-03-01
2012-07-01
Completed
22
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
2013-01-08
2019-07-21
Completed
495
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
2013-02-06
2015-12-10
Completed
183
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
2014-01-31
2021-06-04
Completed
1,846
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
2014-11-12
2017-03-13
Completed
334
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
2015-01-13
2018-11-08
Completed
931
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Multiscan s.r.o." #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Eli Lilly and Company" with 3 trials
sponsored, "Genentech, Inc." with 2 trials sponsored, "Acrotech Biopharma Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc."
with 1 trials sponsored. Other sponsors include -1 different institutions and
companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Multiscan s.r.o."
#1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 9 trials.
Clinical Trials Conditions at Multiscan s.r.o.
According to Clinical.Site data, the most researched conditions in "Multiscan s.r.o." are
"Breast Cancer" (8 trials), "Bladder Cancer" (1 trials), "Breast Neoplasm" (1 trials), "Breast Neoplasms" (1 trials) and "Breast Tumors" (1 trials). Many other conditions were trialed in "Multiscan s.r.o." in a lesser frequency.
Clinical Trials Intervention Types at Multiscan s.r.o.
Most popular intervention types in "Multiscan s.r.o." are "Drug" (19 trials), "Other" (2 trials), "Dietary Supplement" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (7 trials), "Paclitaxel" (6 trials), "Docetaxel" (5 trials), "Atezolizumab" (3 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Multiscan s.r.o.
The vast majority of trials in "Multiscan s.r.o." are
12 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.
Clinical Trials Status at Multiscan s.r.o.
Currently, there are NaN active trials in "Multiscan s.r.o.".
undefined are not yet recruiting,
2 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 9 completed trials in Multiscan s.r.o.,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Multiscan s.r.o., 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".